Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Hepatology

Volumn 58, Issue 6, 2013, Pages 1897-1906

  Younossi, Zobair ^a   Negro, Francesco ^b   Serfaty, Lawrence ^c   Pol, Stanislas ^d   Diago, Moises ^e   Zeuzem, Stefan ^f   Andreone, Pietro ^g   Lawitz, Eric J ^h   Roberts, Stuart ⁱ   Focaccia, Roberto ^j   Foster, Graham R ^k   Horban, Andrzej ^l   Lonjon Domanec, Isabelle ^m   Coate, Bruce ⁿ   Demasi, Ralph ⁿ   Picchio, Gaston ⁿ   Witek, James ⁿ  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Alamo Medical Research   (United States)

ⁱ ALFRED HOSPITAL   (Australia)

^j Emilio Ribas Infectious Diseases Institute   (Brazil)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^l SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^m Janssen Pharmaceuticals   (France)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; RIBAVIRIN; TELAPREVIR; TRIACYLGLYCEROL; ALPHA INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT ESTIMATED INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; GENETICS; HEPATITIS C, CHRONIC; MIDDLE AGED; PHYSIOLOGY; REGRESSION ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84888306778     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26437     Document Type: Article

References (48)

1. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008;49:831-844.
2. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-744.
3. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. Sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Hepatology 2012;56:1681-1687.
4. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-1392.
5. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508.
6. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-117.
7. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009;50:697-706.
8. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010;138:932-941.
9. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34:297-305.
10. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011;55:1187-1194.
11. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.
12. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34.
13. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-1977.
14. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-87.
15. Sherman KE, Flamm SL, Afdhal NH, Flamm S, Afdhal N, Nelson DR, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010;52:401A.
16. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
17. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
18. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012;61:1473-1480.
19. Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, et al. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study. Hepatology 2011;54(Suppl 1):375A.
20. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003;125:1695-1704.
21. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-46.
22. Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008;103:1136-1144.
23. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-423.
24. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-1862.
25. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009;18:2054-2060.
26. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clement S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011;33:1162-1172.
27. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 2004;101:10422-10427.
28. Farrell GC. Signalling links in the liver: knitting SOCS with fat and inflammation. J Hepatol 2005;43:193-196.
29. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003;17:488-490.
30. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009;29:4841-4851.
31. Pascarella S, Clément S, Dill M, Conzelmann S, Lagging M, Missale G, et al. Intrahepatic mRNA levels of the suppressors of cytokine signalling 1 and 3 mRNA are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. Liver Int 2013;33:94-103.
32. Bortoletto G, Scribano L, Realdon S, Marcolongo M, Mirandola S, Franceschini L, et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010;17:475-480.
33. Franceschini L, Realdon S, Marcolongo M, Mirandola S, Bortoletto G, Alberti A. Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance? Hepatology 2011;54:484-494.
34. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006;55:585.
35. Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008;49:295-298.
36. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010;30:447-454.
37. Serfaty L, Fartoux L, Poupon R. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol 2009;50:1269-1271.
38. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012;56:464-473.
39. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
40. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46-52.
41. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601-2608.
42. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
43. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
44. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-648.
45. Pol S, Roberts S, Andreone P, Younossi Z, Diago M, Lawitz EJ, et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study. J Hepatol 2011;54(Suppl 1):S6.
46. Jacobson I, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011;54:S542.
47. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421-429.
48. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012;56:2134-2141.